1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 8 2 Introduction 9 2.1 Bladder and Ureter Cancer Report Coverage 9 2.2 Ureter Cancer – Overview 9 2.3 Bladder Cancer – Overview 9 3 Therapeutics Development 10 3.1 Ureter Cancer 10 3.2 Bladder Cancer 14 4 Therapeutics Assessment 34 4.1 Ureter Cancer 34 4.2 Bladder Cancer 41 5 Companies Involved in Therapeutics Development 58 5.1 Ureter Cancer 58 5.2 Bladder Cancer 61 6 Dormant Projects 125 6.1 Bladder Cancer 125 7 Discontinued Products 131 7.1 Bladder Cancer 131 8 Product Development Milestones 133 8.1 Ureter Cancer 133 8.2 Bladder Cancer 135 9 Appendix 149 9.1 Methodology 149 9.2 Coverage 149 9.3 Secondary Research 149 9.4 Primary Research 149 9.5 Expert Panel Validation 149 9.6 Contact Us 150 9.7 Disclaimer 150

1.1 List of Tables Table 1: Number of Products under Development for Ureter Cancer 10 Table 2: Number of Products under Development by Companies, Ureter Cancer 11 Table 3: Number of Products under Development by Universities/Institutes, Ureter Cancer 12 Table 4: Products under Development by Companies, Ureter Cancer 13 Table 5: Products under Development by Universities/Institutes, Ureter Cancer 13 Table 6: Number of Products under Development for Bladder Cancer 14 Table 7: Number of Products under Development by Companies, Bladder Cancer 16 Table 8: Number of Products under Development by Universities/Institutes, Bladder Cancer 21 Table 9: Products under Development by Companies, Bladder Cancer 22 Table 10: Products under Development by Universities/Institutes, Bladder Cancer 32 Table 11: Number of Products by Stage and Target, Ureter Cancer 35 Table 12: Number of Products by Stage and Mechanism of Action, Ureter Cancer 37 Table 13: Number of Products by Stage and Route of Administration, Ureter Cancer 39 Table 14: Number of Products by Stage and Molecule Type, Ureter Cancer 40 Table 15: Number of Products by Stage and Target, Bladder Cancer 42 Table 16: Number of Products by Stage and Mechanism of Action, Bladder Cancer 48 Table 17: Number of Products by Stage and Route of Administration, Bladder Cancer 55 Table 18: Number of Products by Stage and Molecule Type, Bladder Cancer 57 Table 19: Ureter Cancer – Pipeline by Altor BioScience Corp 58 Table 20: Ureter Cancer – Pipeline by Eisai Co Ltd 58 Table 21: Ureter Cancer – Pipeline by Exelixis Inc 59 Table 22: Ureter Cancer – Pipeline by GlaxoSmithKline Plc 59 Table 23: Ureter Cancer – Pipeline by MedImmune LLC 60 Table 24: Ureter Cancer – Pipeline by Merck & Co Inc 60 Table 25: Bladder Cancer – Pipeline by 4SC AG 61 Table 26: Bladder Cancer – Pipeline by Abivax SA 61 Table 27: Bladder Cancer – Pipeline by Adaptimmune Therapeutics Plc 62 Table 28: Bladder Cancer – Pipeline by ADC Therapeutics Sarl 62 Table 29: Bladder Cancer – Pipeline by Altor BioScience Corp 63 Table 30: Bladder Cancer – Pipeline by AndroScience Corp 63 Table 31: Bladder Cancer – Pipeline by ANP Technologies Inc 64 Table 32: Bladder Cancer – Pipeline by APIM Therapeutics AS 64 Table 33: Bladder Cancer – Pipeline by Archivel Farma SL 65 Table 34: Bladder Cancer – Pipeline by Argos Therapeutics Inc 65 Table 35: Bladder Cancer – Pipeline by Arno Therapeutics Inc 66 Table 36: Bladder Cancer – Pipeline by Array BioPharma Inc 66 Table 37: Bladder Cancer – Pipeline by Asana BioSciences LLC 67 Table 38: Bladder Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd 67 Table 39: Bladder Cancer – Pipeline by Astellas Pharma Inc 68 Table 40: Bladder Cancer – Pipeline by Astex Pharmaceuticals Inc 68 Table 41: Bladder Cancer – Pipeline by AstraZeneca Plc 69 Table 42: Bladder Cancer – Pipeline by AVEO Pharmaceuticals Inc 69 Table 43: Bladder Cancer – Pipeline by Bavarian Nordic A/S 70 Table 44: Bladder Cancer – Pipeline by Bayer AG 70 Table 45: Bladder Cancer – Pipeline by Biocad 71 Table 46: Bladder Cancer – Pipeline by BioCancell Ltd 71 Table 47: Bladder Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd 72 Table 48: Bladder Cancer – Pipeline by Biomics Biotechnologies Co Ltd 72 Table 49: Bladder Cancer – Pipeline by Biotest AG 73 Table 50: Bladder Cancer – Pipeline by Boehringer Ingelheim GmbH 73 Table 51: Bladder Cancer – Pipeline by Bristol-Myers Squibb Co 74 Table 52: Bladder Cancer – Pipeline by Celgene Corp 74 Table 53: Bladder Cancer – Pipeline by Celldex Therapeutics Inc 75 Table 54: Bladder Cancer – Pipeline by Celprogen Inc 75 Table 55: Bladder Cancer – Pipeline by Celsion Corp 76 Table 56: Bladder Cancer – Pipeline by Celyad SA 76 Table 57: Bladder Cancer – Pipeline by Cleveland BioLabs Inc 77 Table 58: Bladder Cancer – Pipeline by Cold Genesys Inc 77 Table 59: Bladder Cancer – Pipeline by Corvus Pharmaceuticals Inc 78 Table 60: Bladder Cancer – Pipeline by CytomX Therapeutics Inc 78 Table 61: Bladder Cancer – Pipeline by Cytori Therapeutics Inc 79 Table 62: Bladder Cancer – Pipeline by Daiichi Sankyo Co Ltd 79 Table 63: Bladder Cancer – Pipeline by Eisai Co Ltd 80 Table 64: Bladder Cancer – Pipeline by Eleven Biotherapeutics Inc 80 Table 65: Bladder Cancer – Pipeline by Eli Lilly and Co 81 Table 66: Bladder Cancer – Pipeline by Elsalys Biotech SAS 82 Table 67: Bladder Cancer – Pipeline by EpiThany Inc 82 Table 68: Bladder Cancer – Pipeline by Esperance Pharmaceuticals Inc 83 Table 69: Bladder Cancer – Pipeline by Exelixis Inc 83 Table 70: Bladder Cancer – Pipeline by Exicure Inc 84 Table 71: Bladder Cancer – Pipeline by F. Hoffmann-La Roche Ltd 84 Table 72: Bladder Cancer – Pipeline by Five Prime Therapeutics Inc 85 Table 73: Bladder Cancer – Pipeline by Gene Signal International SA 85 Table 74: Bladder Cancer – Pipeline by Genentech Inc 86 1.2 List of Figures Figure 1: Number of Products under Development for Ureter Cancer 10 Figure 2: Number of Products under Development by Companies, Ureter Cancer 11 Figure 3: Number of Products under Development by Universities/Institutes, Ureter Cancer 12 Figure 4: Number of Products under Development for Bladder Cancer 14 Figure 5: Number of Products under Development by Companies, Bladder Cancer 15 Figure 6: Number of Products under Development by Universities/Institutes, Bladder Cancer 20 Figure 7: Number of Products by Top 10 Targets, Ureter Cancer 34 Figure 8: Number of Products by Stage and Top 10 Targets, Ureter Cancer 34 Figure 9: Number of Products by Top 10 Mechanism of Actions, Ureter Cancer 36 Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Ureter Cancer 36 Figure 11: Number of Products by Routes of Administration, Ureter Cancer 38 Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Ureter Cancer 38 Figure 13: Number of Products by Molecule Types, Ureter Cancer 39 Figure 14: Number of Products by Stage and Molecule Types, Ureter Cancer 40 Figure 15: Number of Products by Top 10 Targets, Bladder Cancer 41 Figure 16: Number of Products by Stage and Top 10 Targets, Bladder Cancer 41 Figure 17: Number of Products by Top 10 Mechanism of Actions, Bladder Cancer 47 Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bladder Cancer 47 Figure 19: Number of Products by Routes of Administration, Bladder Cancer 54 Figure 20: Number of Products by Stage and Routes of Administration, Bladder Cancer 54 Figure 21: Number of Products by Top 10 Molecule Types, Bladder Cancer 56 Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bladder Cancer 56

4SC AG Abivax SA Adaptimmune Therapeutics Plc ADC Therapeutics Sarl Altor BioScience Corp AndroScience Corp ANP Technologies Inc APIM Therapeutics AS Archivel Farma SL Argos Therapeutics Inc Arno Therapeutics Inc Array BioPharma Inc Asana BioSciences LLC Asieris Pharmaceuticals Co Ltd Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Bavarian Nordic A/S Bayer AG Biocad BioCancell Ltd Biohaven Pharmaceutical Holding Company Ltd Biomics Biotechnologies Co Ltd Biotest AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Celgene Corp Celldex Therapeutics Inc Celprogen Inc Celsion Corp Celyad SA Cleveland BioLabs Inc Cold Genesys Inc Corvus Pharmaceuticals Inc CytomX Therapeutics Inc Cytori Therapeutics Inc Daiichi Sankyo Co Ltd Eisai Co Ltd Eleven Biotherapeutics Inc Eli Lilly and Co Elsalys Biotech SAS EpiThany Inc Esperance Pharmaceuticals Inc Exelixis Inc Exicure Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Gene Signal International SA Genentech Inc Genmab A/S GlaxoSmithKline Plc H3 Biomedicine Inc Hamlet Pharma AB Hanmi Pharmaceuticals Co Ltd HitGen LTD Horizon Pharma Plc Immunocore Ltd Immunomedics Inc Immupharma Plc Imugene Ltd Incanthera Ltd Incyte Corp Innovation Pharmaceuticals Inc InteRNA Technologies BV Iovance Biotherapeutics Inc Johnson & Johnson Kite Pharma Inc Laboratoires Pierre Fabre SA LipoMedix Pharmaceutical Inc Loxo Oncology Inc Lycera Corp MacroGenics Inc Marina Biotech Inc MaxiVAX SA Medicenna Therapeutics Corp MedImmune LLC Merck & Co Inc Merck KGaA Mirati Therapeutics Inc Moleculin Biotech Inc MTG Biotherapeutics Inc NanoCarrier Co Ltd NantKwest Inc Nektar Therapeutics Novartis AG OncoTherapy Science Inc Oncovir Inc Ono Pharmaceutical Co Ltd Optimum Therapeutics LLC Oxford BioTherapeutics Ltd Pfizer Inc Pharma Mar SA Philogen SpA Pieris Pharmaceuticals Inc Plexxikon Inc Polaris Pharmaceuticals Inc Provecs Medical GmbH (Inactive) Provectus Biopharmaceuticals Inc PsiOxus Therapeutics Ltd Rexahn Pharmaceuticals Inc Samyang Holdings Corp Sanofi Sareum Holdings Plc Shionogi & Co Ltd Sierra Oncology Inc Sillajen Biotherapeutics Sitka Biopharma Inc Sorrento Therapeutics Inc Spectrum Pharmaceuticals Inc Stemline Therapeutics Inc Sun Pharma Advanced Research Company Ltd Taiwan Liposome Company Ltd Taris Biomedical LLC Theralase Technologies Inc Tocagen Inc Tolero Pharmaceuticals Inc Transgene SA UroGen Pharma Ltd Vaccibody AS Vakzine Projekt Management GmbH Vault Pharma Inc Vaxeal Holding SA Vaxiion Therapeutics Inc Viralytics Ltd Vyriad Inc Zymeworks Inc